Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy

Chadi Hage, Suzanne Bowyer, Stacey E. Tarvin, Debra Helper, Martin B. Kleiman, L. Joseph Wheat

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Life-threatening histoplasmosis is one of the most common opportunistic infections in patients receiving tumor necrosis factor (TNF) blockers. Delays in considering the diagnosis may lead to increased morbidity and mortality. Most affected patients present with pneumonitis, usually accompanied by additional signs of progressive dissemination, or with signs of progressive dissemination alone. The diagnosis often can be promptly established using antigen detection or direct examination of bronchoalveolar lavage specimens. If histoplasmosis is diagnosed promptly, antifungal therapy is highly effective. After a favorable clinical response, the safety of both discontinuation of antifungal therapy and the resumption of TNF blocker remains undetermined. The management of the immune reconstitution inflammatory syndrome that may follow discontinuation of TNF blockers also requires investigation. Prescribers should become aware of the recognition, diagnosis, and treatment of histoplasmosis and educate recipients about decreasing their risk of exposure and both recognizing and reporting signs of early infection.

Original languageEnglish
Pages (from-to)85-92
Number of pages8
JournalClinical Infectious Diseases
Volume50
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Histoplasmosis
Tumor Necrosis Factor-alpha
Immune Reconstitution Inflammatory Syndrome
Opportunistic Infections
Bronchoalveolar Lavage
Pneumonia
Therapeutics
Morbidity
Safety
Antigens
Mortality
Infection

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. / Hage, Chadi; Bowyer, Suzanne; Tarvin, Stacey E.; Helper, Debra; Kleiman, Martin B.; Wheat, L. Joseph.

In: Clinical Infectious Diseases, Vol. 50, No. 1, 01.2010, p. 85-92.

Research output: Contribution to journalArticle

Hage, Chadi ; Bowyer, Suzanne ; Tarvin, Stacey E. ; Helper, Debra ; Kleiman, Martin B. ; Wheat, L. Joseph. / Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. In: Clinical Infectious Diseases. 2010 ; Vol. 50, No. 1. pp. 85-92.
@article{c8bc7ee99d924953a7d1dbd765e2ba22,
title = "Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy",
abstract = "Life-threatening histoplasmosis is one of the most common opportunistic infections in patients receiving tumor necrosis factor (TNF) blockers. Delays in considering the diagnosis may lead to increased morbidity and mortality. Most affected patients present with pneumonitis, usually accompanied by additional signs of progressive dissemination, or with signs of progressive dissemination alone. The diagnosis often can be promptly established using antigen detection or direct examination of bronchoalveolar lavage specimens. If histoplasmosis is diagnosed promptly, antifungal therapy is highly effective. After a favorable clinical response, the safety of both discontinuation of antifungal therapy and the resumption of TNF blocker remains undetermined. The management of the immune reconstitution inflammatory syndrome that may follow discontinuation of TNF blockers also requires investigation. Prescribers should become aware of the recognition, diagnosis, and treatment of histoplasmosis and educate recipients about decreasing their risk of exposure and both recognizing and reporting signs of early infection.",
author = "Chadi Hage and Suzanne Bowyer and Tarvin, {Stacey E.} and Debra Helper and Kleiman, {Martin B.} and Wheat, {L. Joseph}",
year = "2010",
month = "1",
doi = "10.1086/648724",
language = "English",
volume = "50",
pages = "85--92",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy

AU - Hage, Chadi

AU - Bowyer, Suzanne

AU - Tarvin, Stacey E.

AU - Helper, Debra

AU - Kleiman, Martin B.

AU - Wheat, L. Joseph

PY - 2010/1

Y1 - 2010/1

N2 - Life-threatening histoplasmosis is one of the most common opportunistic infections in patients receiving tumor necrosis factor (TNF) blockers. Delays in considering the diagnosis may lead to increased morbidity and mortality. Most affected patients present with pneumonitis, usually accompanied by additional signs of progressive dissemination, or with signs of progressive dissemination alone. The diagnosis often can be promptly established using antigen detection or direct examination of bronchoalveolar lavage specimens. If histoplasmosis is diagnosed promptly, antifungal therapy is highly effective. After a favorable clinical response, the safety of both discontinuation of antifungal therapy and the resumption of TNF blocker remains undetermined. The management of the immune reconstitution inflammatory syndrome that may follow discontinuation of TNF blockers also requires investigation. Prescribers should become aware of the recognition, diagnosis, and treatment of histoplasmosis and educate recipients about decreasing their risk of exposure and both recognizing and reporting signs of early infection.

AB - Life-threatening histoplasmosis is one of the most common opportunistic infections in patients receiving tumor necrosis factor (TNF) blockers. Delays in considering the diagnosis may lead to increased morbidity and mortality. Most affected patients present with pneumonitis, usually accompanied by additional signs of progressive dissemination, or with signs of progressive dissemination alone. The diagnosis often can be promptly established using antigen detection or direct examination of bronchoalveolar lavage specimens. If histoplasmosis is diagnosed promptly, antifungal therapy is highly effective. After a favorable clinical response, the safety of both discontinuation of antifungal therapy and the resumption of TNF blocker remains undetermined. The management of the immune reconstitution inflammatory syndrome that may follow discontinuation of TNF blockers also requires investigation. Prescribers should become aware of the recognition, diagnosis, and treatment of histoplasmosis and educate recipients about decreasing their risk of exposure and both recognizing and reporting signs of early infection.

UR - http://www.scopus.com/inward/record.url?scp=72049096147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72049096147&partnerID=8YFLogxK

U2 - 10.1086/648724

DO - 10.1086/648724

M3 - Article

VL - 50

SP - 85

EP - 92

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 1

ER -